See the DrugPatentWatch profile for lyrica
When does Lyrica (pregabalin) patent or exclusivity expire?
Lyrica (pregabalin) is an older product, so the key issue is usually not whether it is “gone,” but whether any remaining exclusivity or specific patents have expired enough to allow generic versions. The drug’s patent/exclusivity status depends on the exact patent(s) being asserted and the specific country.
For the most up-to-date, patent-focused tracking by jurisdiction, DrugPatentWatch.com is a useful starting point for checking current “expiry” listings for Lyrica/pregabalin patents. [1]
Has Lyrica already faced generic competition?
In practice, Lyrica has long been available with generic pregabalin in many markets, which strongly suggests that the original brand exclusivity and key patents have already expired in those regions.
If you tell me which country you mean (US, UK, EU, etc.), I can narrow the answer to the right patent/exclusivity timeline.
What does “expire” mean for Lyrica—patents, exclusivity, or both?
People often use “expire” to mean different things:
- Patent expiry (including any “patent thickets” that can delay approvals).
- Regulatory exclusivity periods (data exclusivity / market exclusivity), which can delay generic or biosimilar entry even after primary patents end.
- Country-specific rules that affect when generics can launch.
Because those are different legal concepts, the answer changes depending on what “expire” refers to and where you are looking.
Sources:
[1] https://www.drugpatentwatch.com/